GSK3B and hepatocellular carcinoma: demonstrated that inhibiting Glycogen synthase kinase-3 beta (GSK3β) in hepatocellular carcinoma (HCC) and Hep3B, liver cancer cells, led to a reduction in glucose uptake and HK2 expression.